U.S. market Closed. Opens in 2 hours 1 minute

CDNA | CareDx, Inc Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 21.62 - 22.53
52 Week Range 7.42 - 34.84
Beta 2.90
Implied Volatility 94.44%
IV Rank 23.88%
Day's Volume 543,576
Average Volume 849,992
Shares Outstanding 53,633,900
Market Cap 1,199,790,343
Sector Healthcare
Industry Medical - Diagnostics & Research
IPO Date 2014-07-17
Valuation
Profitability
Growth
Health
P/E Ratio -8.32
Forward P/E Ratio N/A
EPS -2.69
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 635
Country USA
Website CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
CDNA's peers: BNR, CSTL, TWST, BDSX, NTRA, NVTA, CRL, GH, ILMN, MYGN, EXAS, PSNL, SERA, GTH, DRIO, CYRX, FLGT, NEO, OPK, PRPO
*Chart delayed
Analyzing fundamentals for CDNA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see CDNA Fundamentals page.

Watching at CDNA technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on CDNA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙